Search - tctmd.com

Displaying 21 - 33 of 33

Sort: Relevancy | Date

Presentation ECHO 2017

The Role of CMR in Assessing Valvular Heart Disease

Presenter: Mario J. Garcia

April 01, 2017

Presentation TCT 2016

Strengths and Weaknesses of CMR for Quantification of MR

Presenter: Paul A. Grayburn, Patrizio Lancellotti, Stamatios Lerakis

October 30, 2016

Presentation ESC 2016

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

Presenter: John P. Greenwood

August 29, 2016

Presentation

CMR to Evaluate Aortic Regurgitation After TAVR

Presenter: Henrique Ribeiro

August 05, 2016

Presentation

Prognostic Value of CMR and SPECT in Suspected Coronary Heart Disease: CE-MARC Study

Presenter: John P. Greenwood

May 09, 2016

Presentation

Detection of Myocardial Injury by CMR After TAVR

Presenter: W. K. Kim

July 22, 2014

Presentation

CMR Imaging Findings and Risk of CV Events in Patients with Recent MI or Suspected/Known CAD

Presenter: Hamza El Aidi

January 28, 2014

Presentation Cell Therapy 2014

12 months CMR and long-term clinical results of the Swiss AMI Study

Presenter: Daniel S?rder

January 22, 2014

Presentation TCT 2013

Clinical Applications of CMR

Presenter: Stamatios Lerakis

October 27, 2013

Presentation

Prognostic Value of Stress CMR Imaging in Patients with Known or Suspected CAD

Presenter: M.J. Lipinski

May 31, 2013

Presentation

STEM-AMI: cMRI and Other Observations at 3 Years

Presenter: Giulio Pompilio

January 23, 2013

Presentation Cell Therapy 2013

STEM-AMI trial: cMRI and other observations at 3 years

Presenter: Giulio Pompilio

January 22, 2013

Presentation

Diagnostic Performance of Noninvasive MyocardialPerfusion Imaging Using SPECT, CMR, and PET for Detection of Obstructive CAD

Presenter: C. Jaarsma

May 01, 2012

Advertisement

The Role of CMR in Assessing Valvular Heart Disease

Strengths and Weaknesses of CMR for Quantification of MR

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

CMR to Evaluate Aortic Regurgitation After TAVR

Prognostic Value of CMR and SPECT in Suspected Coronary Heart Disease: CE-MARC Study

Detection of Myocardial Injury by CMR After TAVR

CMR Imaging Findings and Risk of CV Events in Patients with Recent MI or Suspected/Known CAD

12 months CMR and long-term clinical results of the Swiss AMI Study

Clinical Applications of CMR

Prognostic Value of Stress CMR Imaging in Patients with Known or Suspected CAD

STEM-AMI: cMRI and Other Observations at 3 Years

STEM-AMI trial: cMRI and other observations at 3 years

Diagnostic Performance of Noninvasive MyocardialPerfusion Imaging Using SPECT, CMR, and PET for Detection of Obstructive CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content